Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $993,185 - $1.13 Million
20,700 New
20,700 $1.12 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $578,900 - $647,300
10,000 New
10,000 $580,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $2.83 Million - $3.2 Million
-43,000 Reduced 63.7%
24,500 $1.7 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $1.38 Million - $1.63 Million
-20,100 Reduced 22.95%
67,500 $4.86 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $2,860 - $1.69 Million
-22,000 Reduced 20.07%
87,600 $6.23 Million
Q2 2022

Aug 17, 2022

BUY
$72.62 - $79.98 $3.06 Million - $3.37 Million
42,100 Added 62.37%
109,600 $8.44 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $2.93 Million - $3.52 Million
47,700 Added 240.91%
67,500 $4.93 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $955,686 - $1.11 Million
17,820 Added 900.0%
19,800 $1.24 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $2.24 Million - $2.62 Million
-37,820 Reduced 95.03%
1,980 $117,000
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $241,449 - $262,938
3,900 Added 10.86%
39,800 $2.66 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $620,046 - $808,794
12,600 Added 54.08%
35,900 $2.3 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $1.17 Million - $1.29 Million
-26,200 Reduced 52.93%
23,300 $1.06 Million
Q1 2019

May 14, 2019

SELL
$45.12 - $53.8 $2 Million - $2.38 Million
-44,300 Reduced 47.23%
49,500 $2.36 Million
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $2.27 Million - $2.95 Million
46,600 Added 98.73%
93,800 $4.88 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $2.6 Million - $2.94 Million
47,200 New
47,200 $2.93 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.